Literature DB >> 28900880

Characterizing Indeterminate Renal Masses with Molecular Imaging: the Role of 99mTc-MIBI SPECT/CT.

Andrew M Reynolds1, Kristin Kelly Porter2.   

Abstract

PURPOSE OF REVIEW: The majority of enhancing renal masses cannot be characterized through imaging as malignant or benign; however, such characterization could save patients from unnecessary surgery and/or biopsy and associated morbidity. Herein, we review the recent literature on the emerging use of 99mTc-MIBI SPECT/CT in preoperative differentiation of enhancing renal masses. RECENT
FINDINGS: Recent reports have shown that 99mTc-MIBI SPECT/CT imaging can differentiate mitochondrial-rich, benign, or indolent renal masses from renal cell carcinoma. These studies demonstrate good correlation between a positive 99mTc-MIBI SPECT/CT scan and a pathologically proven diagnosis of renal oncocytoma and hybrid oncocytic/chromophobe tumor. In addition, there is excellent correlation between a negative scan and a diagnosis of clear cell subtype of renal cell carcinoma. Preoperative 99mTc-MIBI SPECT/CT offers a non-invasive method for differentiating renal lesions with low aggressiveness from other RCCs, in particular, clear cell renal cell carcinoma.

Entities:  

Keywords:  99mTc-MIBI; Oncocytoma; Renal cell carcinoma; Renal mass; Renal sestamibi; SPECT/CT

Mesh:

Substances:

Year:  2017        PMID: 28900880     DOI: 10.1007/s11934-017-0737-0

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  20 in total

1.  Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases.

Authors:  B Delahunt; J N Eble; M R McCredie; P B Bethwaite; J H Stewart; A M Bilous
Journal:  Hum Pathol       Date:  2001-06       Impact factor: 3.466

2.  Guideline for management of the clinical T1 renal mass.

Authors:  Steven C Campbell; Andrew C Novick; Arie Belldegrun; Michael L Blute; George K Chow; Ithaar H Derweesh; Martha M Faraday; Jihad H Kaouk; Raymond J Leveillee; Surena F Matin; Paul Russo; Robert G Uzzo
Journal:  J Urol       Date:  2009-08-14       Impact factor: 7.450

3.  Active surveillance for small renal masses.

Authors:  Phillip M Pierorazio; Elias S Hyams; Jeffrey K Mullins; Mohamad E Allaf
Journal:  Rev Urol       Date:  2012

Review 4.  Preoperative Imaging in Primary Hyperparathyroidism: Literature Review and Recommendations.

Authors:  Stephen Liddy; Daniel Worsley; William Torreggiani; John Feeney
Journal:  Can Assoc Radiol J       Date:  2016-09-24       Impact factor: 2.248

5.  Defining the Added Value of 99mTc-MIBI SPECT/CT to Conventional Cross-Sectional Imaging in the Characterization of Enhancing Solid Renal Masses.

Authors:  Sara Sheikhbahaei; Christopher S Jones; Kristin K Porter; Steven P Rowe; Michael A Gorin; Alex S Baras; Phillip M Pierorazio; Mark W Ball; Takahiro Higuchi; Pamela T Johnson; Lilja B Solnes; Jonathan I Epstein; Mohamad E Allaf; Mehrbod S Javadi
Journal:  Clin Nucl Med       Date:  2017-04       Impact factor: 7.794

Review 6.  Epidemiology of the Small Renal Mass and the Treatment Disconnect Phenomenon.

Authors:  Robert M Turner; Todd M Morgan; Bruce L Jacobs
Journal:  Urol Clin North Am       Date:  2017-03-14       Impact factor: 2.241

7.  Prospective Evaluation of (99m)Tc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors.

Authors:  Michael A Gorin; Steven P Rowe; Alexander S Baras; Lilja B Solnes; Mark W Ball; Phillip M Pierorazio; Christian P Pavlovich; Jonathan I Epstein; Mehrbod S Javadi; Mohamad E Allaf
Journal:  Eur Urol       Date:  2015-09-18       Impact factor: 20.096

Review 8.  The role of 99mTc-sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis.

Authors:  R Taillefer
Journal:  Semin Nucl Med       Date:  1999-01       Impact factor: 4.446

Review 9.  Preoperatively misclassified, surgically removed benign renal masses: a systematic review of surgical series and United States population level burden estimate.

Authors:  David C Johnson; Josip Vukina; Angela B Smith; Anne-Marie Meyer; Stephanie B Wheeler; Tzy-Mey Kuo; Hung-Jui Tan; Michael E Woods; Mathew C Raynor; Eric M Wallen; Raj S Pruthi; Matthew E Nielsen
Journal:  J Urol       Date:  2014-07-27       Impact factor: 7.450

10.  Initial experience using 99mTc-MIBI SPECT/CT for the differentiation of oncocytoma from renal cell carcinoma.

Authors:  Steven P Rowe; Michael A Gorin; Jennifer Gordetsky; Mark W Ball; Phillip M Pierorazio; Takahiro Higuchi; Jonathan I Epstein; Mohamad E Allaf; Mehrbod S Javadi
Journal:  Clin Nucl Med       Date:  2015-04       Impact factor: 7.794

View more
  2 in total

1.  Canadian Urological Association guideline: Management of small renal masses - Full-text.

Authors:  Patrick O Richard; Philippe D Violette; Bimal Bhindi; Rodney H Breau; Wassim Kassouf; Luke T Lavallée; Michael Jewett; John R Kachura; Anil Kapoor; Maxine Noel-Lamy; Michael Ordon; Stephen E Pautler; Frédéric Pouliot; Alan I So; Ricardo A Rendon; Simon Tanguay; Christine Collins; Maryam Kandi; Bobby Shayegan; Andrew Weller; Antonio Finelli; Andrea Kokorovic; Jay Nayak
Journal:  Can Urol Assoc J       Date:  2022-02       Impact factor: 1.862

Review 2.  A review of 99mTc-sestamibi SPECT/CT for renal oncocytomas: A modified diagnostic algorithm.

Authors:  Mitchell P Wilson; Prayash Katlariwala; Jonathan Abele; Gavin Low
Journal:  Intractable Rare Dis Res       Date:  2022-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.